학술논문
Single-cell sequencing in primary intraocular tumors: understanding heterogeneity, the microenvironment, and drug resistance.
Document Type
Academic Journal
Author
He LF; Department of Ophthalmology, Changzheng Hospital of Naval Medical University, Shanghai, China.; Mou P; Department of Ophthalmology, Changzheng Hospital of Naval Medical University, Shanghai, China.; Yang CH; Department of Ophthalmology, Changzheng Hospital of Naval Medical University, Shanghai, China.; Huang C; 92882 Troops of the Chinese People's Liberation Army, Qingdao, China.; Shen Y; Department of Ophthalmology, Changzheng Hospital of Naval Medical University, Shanghai, China.; Zhang JD; Department of Ophthalmology, Changzheng Hospital of Naval Medical University, Shanghai, China.; Wei RL; Department of Ophthalmology, Changzheng Hospital of Naval Medical University, Shanghai, China.
Source
Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Subject
Language
English
Abstract
Retinoblastoma (RB) and uveal melanoma (UM) are the most common primary intraocular tumors in children and adults, respectively. Despite continued increases in the likelihood of salvaging the eyeball due to advancements in local tumor control, prognosis remains poor once metastasis has occurred. Traditional sequencing technology obtains averaged information from pooled clusters of diverse cells. In contrast, single-cell sequencing (SCS) allows for investigations of tumor biology at the resolution of the individual cell, providing insights into tumor heterogeneity, microenvironmental properties, and cellular genomic mutations. SCS is a powerful tool that can help identify new biomarkers for diagnosis and targeted therapy, which may in turn greatly improve tumor management. In this review, we focus on the application of SCS for evaluating heterogeneity, microenvironmental characteristics, and drug resistance in patients with RB and UM.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 He, Mou, Yang, Huang, Shen, Zhang and Wei.)
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 He, Mou, Yang, Huang, Shen, Zhang and Wei.)